AstraZeneca Nexium Labeling In Sweden Cites 93% GERD Healing At 8 Weeks
Executive Summary
AstraZeneca's proton pump inhibitor Nexium demonstrates a 93% healing rate in erosive reflux esophagitis, according to Swedish labeling for the drug.
You may also be interested in...
AstraZeneca Ramps Up U.S. Sales Force Before Nexium, Statin Launches
AstraZeneca plans to hire more in-house sales reps and decrease its "substantial reliance on contract sales organizations," Senior VP-Commercialization and Portfolio Management David Brennan said at the company's half-year results presentation in London Aug. 1.
AstraZeneca Ramps Up U.S. Sales Force Before Nexium, Statin Launches
AstraZeneca plans to hire more in-house sales reps and decrease its "substantial reliance on contract sales organizations," Senior VP-Commercialization and Portfolio Management David Brennan said at the company's half-year results presentation in London Aug. 1.
AstraZeneca Nexium NDA Includes "On-Demand" Dosing
AstraZeneca's NDA for the Prilosec follow-on product Nexium includes an indication for "on demand" maintenance treatment for gastroesophageal reflux disease.